Figure 3 from Mechanisms Underlying Cedazuridine-Mediated Enhancement of Oral Decitabine Bioavailability

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Cedazuridine increases urinary excretion of decitabine independent of CDA. A, Schematic of experimental design. Mice received oral decitabine (10 mg/kg) with or without oral cedazuridine (3 mg/kg) and were housed in metabolic cages for urine and feces collection. At study endpoint, tissues and excreta were harvested and analyzed for radioactivity to quantify drug distribution and excretion. B, Distribution of total administered decitabine dose across plasma, urine, and feces in WT and CDA-KO mice. In WT animals, co-administration of cedazuridine significantly increased the fraction of decitabine excreted in urine compared with decitabine alone. A similar increase in urinary excretion was observed in CDA-KO mice. Data are presented as mean ± SEM (n = 3 mice per group). ***, P < 0.001; ****, P < 0.0001.